Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

December 15, 2025

Study Completion Date

July 15, 2026

Conditions
Hypercholesterolemia, Autosomal DominantHypercholesterolemia, Autosomal RecessiveFamilial Combined Hypercholesterolemia
Interventions
GENETIC

Whole Genome Sequencing

Participants in this arm will have their blood sample analyzed by whole-genome sequencing (WGS) and will be given access to Predictiv™ Deoxyribonucleic acid (DNA)-based digital twin platform, a web-based interactive application with WGS results. The platform will include positive monogenic and polygenic Familial Hypercholesterolemia results and pharmacogenomics results on statins and clopidogrel. A report of positive monogenic variants will be included in their medical record. This may also include genes on the American College of Medical Genetics and Genomics (ACMG) secondary findings (SF) version 3.2 list if the participant consents to receive these incidental findings. The report will only include pathogenic, likely pathogenic, and variant of uncertain significance (VUS) results.

Trial Locations (1)

Unknown

RECRUITING

Abu Dhabi Health Research Center, Abu Dhabi

All Listed Sponsors
collaborator

Predictiv Care, Inc.

INDUSTRY

lead

Abu Dhabi Health Services Company

OTHER_GOV